keyword
MENU ▼
Read by QxMD icon Read
search

opioid maintenance treatment

keyword
https://www.readbyqxmd.com/read/28509817/modified-delphi-process-for-the-development-of-choosing-wisely-for-inflammatory-bowel-disease
#1
Geoffrey C Nguyen, Karen Boland, Waqqas Afif, Brian Bressler, Jennifer L Jones, Adam V Weizman, Sharyle Fowler, Smita Halder, Vivian W Huang, Gilaad G Kaplan, Reena Khanna, Sanjay K Murthy, Joannie Ruel, Cynthia H Seow, Laura E Targownik, Tanya Chawla, Luis Guimaraes, Aida Fernandes, Sherif Saleh, Gil Y Melmed
BACKGROUND AND AIMS: The prevalence and incidence of inflammatory bowel disease (IBD) in North America is among the highest in the world and imparts substantial direct and indirect medical costs. The Choosing Wisely Campaign was launched in wide variety of medical specialties and disciplines to reduce unnecessary or harmful tests or treatment interventions. METHODS: The Choosing Wisely list for IBD was developed by the Canadian IBD Network for Research and Growth in Quality Improvement (CINERGI) in collaboration with Crohn's and Colitis Canada (CCC) and the Canadian Association of Gastroenterology (CAG)...
June 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28509768/modified-delphi-process-for-the-development-of-choosing-wisely-for-inflammatory-bowel-disease
#2
Geoffrey C Nguyen, Karen Boland, Waqqas Afif, Brian Bressler, Jennifer L Jones, Adam V Weizman, Sharyle Fowler, Smita Halder, Vivian W Huang, Gilaad G Kaplan, Reena Khanna, Sanjay K Murthy, Joannie Ruel, Cynthia H Seow, Laura E Targownik, Tanya Chawla, Luis Guimaraes, Aida Fernandes, Sherif Saleh, Gil Y Melmed
BACKGROUND AND AIMS: The prevalence and incidence of inflammatory bowel disease (IBD) in North America is among the highest in the world and imparts substantial direct and indirect medical costs. The Choosing Wisely Campaign was launched in wide variety of medical specialties and disciplines to reduce unnecessary or harmful tests or treatment interventions. METHODS: The Choosing Wisely list for IBD was developed by the Canadian IBD Network for Research and Growth in Quality Improvement (CINERGI) in collaboration with Crohn's and Colitis Canada (CCC) and the Canadian Association of Gastroenterology (CAG)...
May 15, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28493264/drop-out-from-a-drug-treatment-clinic-and-associated-reasons
#3
Leila Hoseinie, Zhaleh Gholami, Behrang Shadloo, Azarakhsh Mokri, Masoumeh Amin-Esmaeili, Afarin Rahimi-Movaghar
The aim of this study was to assess drop-out rates and associated reasons among patients at the Iranian National Center for Addiction Studies (INCAS) clinic. In a one-year period (April 2014 to March 2015), all patients with drug dependence who had been referred for treatment and attended for a first assessment were included in this study (N=242). Those who received treatment were followed until March 2016. Survival analysis showed that 70.2% had dropped out from treatment. Log rank test showed that treatment drop-out rates differed between the different approaches used (P < 0...
May 1, 2017: Eastern Mediterranean Health Journal, la Revue de Santé de la Méditerranée Orientale
https://www.readbyqxmd.com/read/28492461/overcoming-barriers-to-initiating-medication-assisted-treatment-for-heroin-use-disorder-in-a-general-medical-hospital-a-case-report-and-narrative-literature-review
#4
Sameer Hassamal, Matthew Goldenberg, Waguih Ishak, Margaret Haglund, Karen Miotto, Itai Danovitch
Deaths due to heroin overdoses are increasing and are the leading cause of death among intravenous heroin users. Although medication-assisted treatment (MAT) improves morbidity and mortality in patients with opioid use disorders, it is underutilized. Most efforts to expand access to MAT have focused on outpatient settings. Although the inpatient medical setting presents a critical opportunity to initiate treatment, general hospitals are often unfamiliar with MAT, creating a number of barriers to its use. In this report, we describe the case of a woman with heroin use disorder who was initiated on buprenorphine maintenance treatment while hospitalized for cardiac disease related to her intravenous heroin use...
May 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28489467/use-of-opioid-substitution-therapies-in-the-treatment-of-opioid-use-disorder-results-of-a-uk-cost-effectiveness-modelling-study
#5
James Kenworthy, Yunni Yi, Antony Wright, Jim Brown, Ana Maria Madrigal, William C N Dunlop
AIMS: We investigated the cost-effectiveness of buprenorphine maintenance treatment (BMT) and methadone maintenance treatment (MMT) versus no opioid substitution therapy (OST) for the treatment of opioid use disorder, from the UK National Health Service (NHS)/personal social services (PSS) and societal perspectives over one year. METHODS: Cost-effectiveness of OST versus no OST was evaluated by first replicating and then expanding an existing UK health technology assessment model...
May 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28480247/infectious-disease-id-learning-unit-what-the-id-clinician-needs-to-know-about-buprenorphine-treatment-for-opioid-use-disorder
#6
Amanda A Westlake, Mark P Eisenberg
In the context of an escalating opioid epidemic, infectious disease clinicians increasingly treat the infectious complications of injection drug use. In this learning unit, we review the history, pharmacology, and clinical use of buprenorphine as maintenance therapy for opioid use disorder, and we describe the process by which clinicians can obtain a buprenorphine waiver.
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28479216/design-and-implementation-of-a-factorial-randomized-controlled-trial-of-methadone-maintenance-therapy-and-an-evidence-based-behavioral-intervention-for-incarcerated-people-living-with-hiv-and-opioid-dependence-in-malaysia
#7
Alexander R Bazazi, Jeffrey A Wickersham, Martin P Wegman, Gabriel J Culbert, Veena Pillai, Roman Shrestha, Haider Al-Darraji, Michael M Copenhaver, Adeeba Kamarulzaman, Frederick L Altice
Incarcerated people living with HIV and opioid dependence face enormous challenges to accessing evidence-based treatment during incarceration and after release into the community, placing them at risk of poor HIV care outcomes as well as relapse to opioid use and accompanying HIV transmission risk behaviors. Here we describe in detail the design and implementation of Project Harapan, a prospective clinical trial conducted among people living with HIV and opioid dependence who transitioned from prison to the community in Malaysia from 2010 to 2014...
May 4, 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/28476272/factors-associated-with-ongoing-criminal-engagement-while-in-opioid-maintenance-treatment
#8
Marianne Riksheim Stavseth, Jo Røislien, Anne Bukten, Thomas Clausen
INTRODUCTION: This study examines factors associated with criminal engagement among patients in opioid maintenance treatment (OMT). METHODS: Questionnaire data recorded annually among 5654 patients in the Norwegian OMT programme between 2005 and 2010 from seven regional treatment centres were available for analyses. Each patient answered approximately 4 times (mean: 4.11, SD: 1.46) generating a total of 18,538 questionnaires. The outcome variable of the study, engagement in criminal activity, was defined as whether a patient had been arrested, put in custody, been charged and/or convicted of a crime within the last 12months prior to the completion of the questionnaire...
June 2017: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/28474460/long-term-efficacy-and-safety-of-oxycodone-naloxone-prolonged-release-formulation-up-to-180-90-mg-daily-results-of-the-open-label-extension-phase-of-a-phase-iii-multicenter-multiple-dose-randomized-controlled-study
#9
D Dupoiron, A Stachowiak, O Loewenstein, A Ellery, W Kremers, B Bosse, M Hopp
BACKGROUND: The inclusion of naloxone with oxycodone in a fixed combination prolonged-release formulation (OXN PR) improves bowel function compared with oxycodone (Oxy) alone without compromising analgesic efficacy. In a recent 5-week, randomized, double-blind comparative trial of OXN PR and OxyPR, it could be shown that the beneficial properties of OXN PR extend to doses up to 160/80 mg. METHODS: Bowel function, pain, quality of life (QoL) and safety of OXN PR up to 180/90 mg daily were evaluated in a 24-week open-label extension phase of the 5-week randomized comparative study in patients with non-malignant or malignant pain requiring opioids and suffering from opioid-induced constipation...
May 4, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/28471281/is-a-history-of-sexual-abuse-related-to-poor-sleep-among-former-opioid-addicted-women-with-and-without-methadone-maintenance-treatment
#10
Einat Peles, Shay Hacohen, Anat Sason, Smadar Lamberg, Shaul Schrieber, Miriam Adelson
To study whether poor sleep that is known to characterize methadone maintenance treatment (MMT) patients may be related to their past sexual abuse and/or their treatment modality, we compared perceived sleep indices (Pittsburgh Sleep Quality Index (PSQI); Epworth Sleepiness Scale (ESS)) and depression (21-HAM-D) between women with and without sexual abuse history (Childhood Trauma Questionnaire) in MMT and in a non-MMT ("opioid medication-free") in-patient rehabilitation center (MABAT). Twenty-six sexually abused women in MMT had the worst sleep quality scores (PSQI) (10...
May 4, 2017: Substance Use & Misuse
https://www.readbyqxmd.com/read/28466423/chronic-pruritus-current-and-emerging-treatment-options
#11
REVIEW
Manuel P Pereira, Sonja Ständer
Chronic pruritus remains a central societal issue because of its high occurrence and the substantial decrease in quality of life it may cause to affected individuals. Not only dermatological conditions, but also systemic, neurological, or psychiatric diseases may lead to chronic pruritus. Additionally, various underlying conditions may coexist or the cause may be unknown. Due to its heterogeneity, the therapeutic approach is complex and remains a challenge for the clinician. Basic measures such as emollients to avoid xerosis and treatment of the underlying disease should be initiated regardless of the duration of the symptom...
June 2017: Drugs
https://www.readbyqxmd.com/read/28454045/canadian-harm-reduction-policies-a-comparative-content-analysis-of-provincial-and-territorial-documents-2000-2015
#12
REVIEW
T Cameron Wild, Bernie Pauly, Lynne Belle-Isle, Walter Cavalieri, Richard Elliott, Carol Strike, Kenneth Tupper, Andrew Hathaway, Colleen Dell, Donald MacPherson, Caitlin Sinclair, Kamagaju Karekezi, Benjamin Tan, Elaine Hyshka
BACKGROUND: Access to harm reduction interventions among substance users across Canada is highly variable, and largely within the policy jurisdiction of the provinces and territories. This study systematically described variation in policy frameworks guiding harm reduction services among Canadian provinces and territories as part of the first national multimethod case study of harm reduction policy. METHODS: Systematic and purposive searches identified publicly-accessible policy texts guiding planning and organization of one or more of seven targeted harm reduction services: needle distribution, naloxone, supervised injection/consumption, low-threshold opioid substitution (or maintenance) treatment, buprenorphine/naloxone (suboxone), drug checking, and safer inhalation kits...
April 25, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28454044/unintended-impacts-of-regulatory-changes-to-british-columbia-methadone-maintenance-program-on-addiction-and-hiv-related-outcomes-an-interrupted-time-series-analysis
#13
M Eugenia Socías, Evan Wood, Ryan McNeil, Thomas Kerr, Huiru Dong, Jean Shoveller, Julio Montaner, M-J Milloy
BACKGROUND: In February 2014, several regulatory reforms were introduced to the methadone maintenance treatment (MMT) program in British Columbia, Canada, including a switch to a ten-times more concentrated methadone formulation and restrictions in pharmacy delivery services. We evaluated possible unintended effects of these changes on illicit drug use patterns and HIV treatment outcomes among HIV-positive opioid users. METHODS: Data was drawn from ACCESS, a prospective community-recruited cohort of HIV-positive people who use illicit drugs in Vancouver, Canada...
April 25, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28450464/positive-percentages-of-urine-morphine-tests-among-methadone-maintenance-treatment-clients-with-hiv-aids-a-12-month-follow-up-study-in-guangdong-province-china
#14
Xiaofeng Luo, Xiao Gong, Peizhen Zhao, Xia Zou, Wen Chen, Li Ling
OBJECTIVE: We aimed to assess the positive percentages of urine morphine tests and correlates among methadone maintenance treatment (MMT) clients with HIV/AIDS in Guangdong, China. SETTING: Fourteen MMT clinics located in nine cities of Guangdong were chosen as study sites. PARTICIPANTS: In this study, we reviewed 293 clients with opioid dependence, who were HIV seropositive, 18 years or older, provided informed consent and had at least 10 records of urine morphine tests during the study period...
April 27, 2017: BMJ Open
https://www.readbyqxmd.com/read/28393896/effects-of-ibudilast-on-the-subjective-reinforcing-and-analgesic-effects-of-oxycodone-in-recently-detoxified-adults-with-opioid-dependence
#15
Verena E Metz, Jermaine D Jones, Jeanne Manubay, Maria A Sullivan, Shanthi Mogali, Andrew Segoshi, Gabriela Madera, Kirk W Johnson, Sandra D Comer
Ibudilast, a nonselective phosphodiesterase inhibitor, is used clinically in Asia for the treatment of asthma and poststroke dizziness. Recent preclinical studies have suggested that it also inhibits glial cell activation in rodents, and may alter opioid-mediated effects, including analgesia and withdrawal symptoms. The effects of ibudilast on the abuse potential of opioids in humans are largely unknown. The present study was designed to examine the influence of ibudilast on subjective (including drug craving), reinforcing, and analgesic effects of oxycodone in human volunteers diagnosed with opioid dependence (equivalent to moderate-severe opioid use disorder)...
May 10, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28376505/six-year-outcome-of-opioid-maintenance-treatment-in-heroin-dependent-patients-results-from-a-naturalistic-study-in-a-nationally-representative-sample
#16
Michael Soyka, Jens Strehle, Jürgen Rehm, Gerhard Bühringer, Hans-Ulrich Wittchen
BACKGROUND: In many countries, the opioid agonists, buprenorphine and methadone, are licensed for maintenance treatment of opioid dependence. Many short-term studies have been performed, but little is known about long-term effects. Therefore, this study described over 6 years (1) mortality, retention and abstinence rates and (2) changes in concomitant drug use and somatic and mental health. METHODS: A prevalence sample of n = 2,694 maintenance patients, recruited from a nationally representative sample of n = 223 substitution doctors, was evaluated in a 6-year prospective-longitudinal naturalistic study...
2017: European Addiction Research
https://www.readbyqxmd.com/read/28374922/synovial-membrane-receptors-as-therapeutic-targets-a-review-of-receptor-localization-structure-and-function
#17
REVIEW
Stephanie A Kleine, Steven C Budsberg
Joint pathology and degeneration is a significant cause of pain. The synovial membrane plays an important role in maintenance of the joint, contributes to the pathology of many arthropathies and may be adversely affected in joint disease. Improving knowledge of the receptors present within the synovium will aid in a better understanding of joint pathology and the development of new treatments for diseases such as osteoarthritis and rheumatoid arthritis. Knowledge of the location and function of synovial membrane receptors (both in healthy and diseased synovium) may provide important targets in the treatment of various arthropathies...
April 4, 2017: Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society
https://www.readbyqxmd.com/read/28371835/effectiveness-and-safety-of-once-daily-extended-release-hydrocodone-in-individuals-previously-receiving-immediate-release-oxycodone-for-chronic-pain
#18
Joseph Pergolizzi, Maribeth Kowalski, Ellie He
Objectives. : This study evaluated the safety and effectiveness of a once-daily, single-entity, extended-release hydrocodone bitartrate (HYD) among patients with chronic noncancer and non-neuropathic pain who required opioid rotation from a previous analgesic regimen that primarily consisted of immediate-release (IR) oxycodone. Methods. : Post hoc analyses of a primary study that assessed HYD 20 to 120 mg over a 52-week period are presented. The primary study included a dose titration period (up to 45 days), a 52-week maintenance period, and an optional taper period (up to 14 days)...
March 28, 2017: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/28367308/association-between-cannabis-use-and-methadone-maintenance-treatment-outcomes-an-investigation-into-sex-differences
#19
Laura Zielinski, Meha Bhatt, Nitika Sanger, Carolyn Plater, Andrew Worster, Michael Varenbut, Jeff Daiter, Guillaume Pare, David C Marsh, Dipika Desai, James MacKillop, Meir Steiner, Stephanie McDermid Vaz, Lehana Thabane, Zainab Samaan
BACKGROUND: Cannabis will soon become legalized in Canada, and it is currently unclear how this will impact public health. Methadone maintenance treatment (MMT) is the most common pharmacological treatment for opioid use disorder (OUD), and despite its documented effectiveness, a large number of patients respond poorly and experience relapse to illicit opioids. Some studies implicate cannabis use as a risk factor for poor MMT response. Although it is well established that substance-use behaviors differ by sex, few of these studies have considered sex as a potential moderator...
2017: Biology of Sex Differences
https://www.readbyqxmd.com/read/28358754/open-label-study-of-injectable-extended-release-naltrexone-xr-ntx-in-healthcare-professionals-with-opioid-dependence
#20
Paul H Earley, Jacqueline Zummo, Asli Memisoglu, Bernard L Silverman, David R Gastfriend
OBJECTIVES: Healthcare professionals (HCPs) with opioid dependence are at risk for relapse and death, particularly in the first year of recovery; however, maintenance treatment with opioid agonists is controversial in this safety-sensitive group. We evaluated long-term safety, tolerability, and treatment outcomes of injectable, intramuscular, extended-release naltrexone (XR-NTX) in opioid-dependent HCPs. METHODS: This single-arm, multisite, open-label study was conducted in opioid-dependent HCPs who had been detoxified from opioids for at least 2 weeks...
March 29, 2017: Journal of Addiction Medicine
keyword
keyword
71692
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"